U.S. markets ended Thursday with mixed performance: the Dow Jones Industrial Average climbed 0.4% to 43,239.05, the S&P 500 held steady at 5,841.47, and the Nasdaq inched up by 0.04% to close at ...

Northwestern University sued vaccine maker Moderna, Inc. on Wednesday, October 16, in the U.S. District Court for the ...

Moderna is facing allegations that it misused innovations from researchers at Northwestern University to develop its mRNA COVID-19 vaccines, which became widely available to the public in 2021 to ...

Factors associated with increased flare rates post-vaccination included active disease at the time, female sex, and -- most ...

Jefferies analyst Michael Yee maintained a Hold rating on Moderna (MRNA – Research Report) today and set a price target of $55.00. The ...

Northwestern University has filed a lawsuit against Moderna, alleging the company used its patented lipid nanoparticle ...

A new study has provided a detailed analysis of how mRNA vaccines circulate and break down in the human bloodstream. The research aimed to help improve the safety and effectiveness of these vaccines, ...

Moderna was hit with a new patent lawsuit on Wednesday in Delaware federal court from Northwestern University, which accused ...

A British drugmaker, GlaxoSmithKline (GSK), has sued American pharmaceutical company Moderna claiming it violated patent ...

We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In this article, we are going ...

A study led by researchers from RMIT University and the Doherty Institute has provided the first detailed analysis of how mRNA vaccines circulate and break down in the human bloodstream.

The hold, which was made in response to a serious adverse event report, could impact the company’s plans to start a Phase 3 trial of a combination shot for COVID-19 and influenza.